Matt Henriksen

It's, you know, we talk about the, you know, two feet of snow outside.

But the last time we had a major snowstorm was 2021.

And then 2016 was also that crazy one.

So it just got to be coincidence.

But I'd love to hear your thoughts about how this new randomized trial is going to, you know, be that next catalyst or that next inflection point for kind of the adoption of these CGM products.

Yeah.

And so, you know, because the patient base is different, are the endpoints different in any way?

I know with the diamond and the mobile, you know, you looked at the reduction in A1C, you looked at increases in the time and healthy glucose ranges.

Are those kind of the same metrics that you're looking at comparing between the CGM and, you know, the standard of care?

Yeah.

And then is it when you talk about the CGM, because we were talking about the, you know, expanding the reimbursement coverage for G7.

Is the G7 the one being used in this trial or is it Stella or is it either?

Yeah.

We're talking a lot about the product development, but there's also the commercial expansion.

And because, you know, the U.S.

market is, you know, I feel more accustomed to the CGM technology that's out there and the penetration rate is higher, but you still have the large international opportunity.

So what is the strategy in 2026 to kind of keep that expansion going in the OUS countries?

Yeah.

And with that market expansion, obviously the next natural question is the competitive landscape.

My observation over the last few years is that new companies are trying to enter this market.